Ligand

Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit

Retrieved on: 
Monday, June 5, 2023
RA, Macrophage, IBD, Ligand, Gene expression, Inflammation, Ulcerative colitis, Inflammatory bowel disease, Patient, Immune system, Phenotype, Gene, Autoimmunity, Rheumatoid arthritis, Pharmaceutical industry, CD69, Regulatory T cell, Revolo

“This compelling data shows that ‘1805 enhances CD69+ and CD39+ Tregs in human tissue afflicted with IBD and improves anti-inflammatory gene transcription.

Key Points: 
  • “This compelling data shows that ‘1805 enhances CD69+ and CD39+ Tregs in human tissue afflicted with IBD and improves anti-inflammatory gene transcription.
  • This further illustrates ‘1805 unique mechanism of action as it resets the immune system to restore immune system balance,” said Jonathan Rigby, Chief Executive Officer of Revolo.
  • “Additional data for ‘1805 in immune cells harvested from patients with RA showcases the selective alteration of RA cell transcripts compared to controls.
  • When CD69 binds to its ligands, the JAK/STAT5 pathway is activated to promote Treg differentiation and prevent pro-inflammatory Th1/Th7 cell generation.

Philogen Announces Clinical Trial Collaboration with MSD

Retrieved on: 
Thursday, June 1, 2023
MSD, Tissue, Antigen, Intellectual property, IV, Chemical library, CSO, Ligand, Research, Blood, Clinical trial, Patient, Melanoma, Merck, Merck & Co., PD-1, Phase, Pembrolizumab, IL2, III, Merck Sharp & Dohme Federal Credit Union, Disease, Pharmaceutical industry, Vaccine, Jaden Philogene

The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors

Key Points: 
  • The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitors
    Siena, Italy, June 1st, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative medicines based on tumor-targeting antibodies and small molecule ligands, announces that it has entered into a Clinical Trial Collaboration and Supply Agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA).
  • Under the terms of the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy™ in a randomized Phase II clinical trial.
  • Dario Neri, CEO and CSO of Philogen, commented: "KEYTRUDA® has shown impressive response rates and long-term benefits for a substantial number of patients with advanced melanoma.
  • Nidlegy™ is a registered trademark of Philogen S.p.A. of La Lizza 7, 53100 Siena, ITALY.

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

Ligand Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Telephone, Fulvestrant, GAAP, Congress, Investment, Focal segmental glomerulosclerosis, Patient, NYSE, PROTECT, Novartis, LGG, NASH, Mutation, Element, Forecasting, EMA, Proteinuria, Molluscum contagiosum, PDUFA, Growth, SB206, FDA, Lancet, THC, Total, Safety, Pelican, CDK, Microcystic lymphatic malformation, COVID-19, FSGS, BRAF, Immunoglobulin A, Research, Therapy, NVS, ESR1, NDA, Income tax, Woman, Sale, Trial of the century, Nephrology, Physician, EPS, Breast cancer, Cryptocurrency, Pharmaceutical industry, Travers Smith, Ligand, IgA nephropathy

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates.
  • Core Captisol sales were $10.6 million for the first quarter of 2023, compared with $6.2 million for the same period in 2022.
  • Contract revenue was $16.2 million for the first quarter of 2023, compared with $11.0 million for the same period in 2022.
  • Ligand is increasing 2023 revenue and EPS guidance provided on its fourth quarter earnings call held on February 22, 2023.

OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech

Retrieved on: 
Thursday, May 4, 2023
Faculty, ICIS, Partnership, Drug development, ICI, Ligand, Cancer, Henney Kilowatt, Biomarker, Immunotherapy, Oncology, Patient, Physician, Medicine, PD-L2, BGU, Diagnosis, Ben-Gurion University of the Negev, PD-1, PD-L1, Palladium, Pharmaceutical industry, Medical imaging

BEER-SHEVA, Israel and BINYAMINA, Israel, May 4, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has signed an option agreement with BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), to receive a license for a novel biosensing technology called IcAR (Immuno-checkpoint Artificial Reporter). IcAR was developed by a team of researchers from BGU.

Key Points: 
  • With only 20-40% of cancer patients responding to immune checkpoint inhibitor (ICI) treatment, better biomarkers are desperately needed.
  • The IcAR biosensing technology measures the binding functionality of PD-1 ligands, PD-L1 and PD-L2, to their receptor, PD-1.
  • "IcAR technology is expected to be a game-changer in the world of cancer treatment diagnostics," said Prof. Elkabets.
  • In the future, this bioassay technology may help predict response to additional ICI therapies and could be used to tailor personalized treatment protocols.

Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant

Retrieved on: 
Thursday, May 4, 2023
Sclerosis, Tonix Pharmaceuticals, MGH, Therapy, TNF, Osteoporosis, Hook effect, Massachusetts General Hospital, Ligand, Doctor of Philosophy, Organ transplantation, Ulcerative colitis, Harvard Medical School, Transplant, Thrombosis, Investigational New Drug, MD, Patient, Gujarat University of Transplantation Sciences, Primate, Mab, Protein engineering, Hospital, FDA, HMS, CD40L, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, TL1A, Food, RANKL, Pharmaceutical industry, Dentistry

CHATHAM, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 1 clinical trial with TNX-1500 (anti-CD40L monoclonal antibody [mAb]). The first indication Tonix is seeking for TNX-1500 is the prevention of organ rejection in patients receiving a kidney transplant. The Company expects to initiate enrollment in the Phase 1 study in the third quarter of 2023.

Key Points: 
  • The first indication Tonix is seeking for TNX-1500 is the prevention of organ rejection in patients receiving a kidney transplant.
  • “This is an important milestone as we advance TNX-1500 into clinical development,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection.
  • Preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft organ rejection and was well tolerated1,2.

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody

Retrieved on: 
Thursday, April 27, 2023
Yale University, Health Affairs, Therapy, Senior, GBM, Journal, Critical Care Medicine (journal), Prior, Cancer research, RI, Neoplasm, Ligand, University, Dean, Yale New Haven Hospital, Research, Cell, Lung cancer, Antibody, Doctor of Philosophy, Thought, Plasticity, MRI, CTLA4, Biology, Protein, Science, MD, Chandos Chair of Medicine and Anatomy, PTEN, Patient, Melanoma, Brown University, Apoptosis, Cancer, Mouse, Growth, PD-1, IND, PD-L1, Environment, Phenotype, Laboratory, Metastasis, Disease, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Glioblastoma, Frontiers, Ocean Biomedical, CHI3L1, Immunology, Medicine

Providence, RI, April 27, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, published new findings in the peer-reviewed journal Cancer Research that detail the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors, providing further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth.

Key Points: 
  • In two different study approaches, treatment with anti-Chi3L1 antibody in vivo resulted in over 60% reduction of human glioblastoma growth, and significant survival benefit.
  • This represents a medical breakthrough in understanding how the most aggressive glioblastoma tumors are formed, and how patients diagnosed with this challenging disease might possibly be treated.
  • “This is a completely new way of thinking about how to treat this tumor.
  • Knowing the drivers for this heterogeneity, this is the holy grail for glioblastoma.”

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Retrieved on: 
Thursday, March 30, 2023
WCN, Survival, Ligand, ID, Net, Congress, Patient, Organ transplantation, Kidney transplantation, Kidney, Webcast, United Kingdom, Eledone massyae, Research, ALS, Three Months, ChromeOS, Safety, Pharmaceutical industry, Cryptocurrency, IgA nephropathy

IRVINE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its fourth quarter and full-year 2022 operating and financial results and reviewed recent business highlights.

Key Points: 
  • Eledon will share safety and efficacy results from the first three participants at the WCN, taking place March 30 – April 2, 2023 in Bangkok, Thailand.
  • Eledon deprioritized the clinical development of tegoprubart in IgA Nephropathy (IgAN) and discontinued its Phase 1/2 trial for islet cell transplantation.
  • The net loss for the three months ended December 31, 2022 includes a non-cash goodwill impairment charge totaling $48.6 million.
  • Eledon will hold a conference call today, March 30, 2023 at 4:30 pm Eastern Time to discuss fourth quarter and full-year 2022 results.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Retrieved on: 
Tuesday, March 28, 2023
Tissue, Antigen, Intellectual property, DNA, Chemical library, Renal cell carcinoma, Dels, Ligand, Research, HIT, Blood, Protein, CAIX, Machine learning, DEL, Carbonic anhydrase, Drug discovery, Artificial intelligence, Neoplasm, Hypoxia, DNA-encoded chemical library, Vaccine, Pharmaceutical industry, Jaden Philogene

Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).

Key Points: 
  • Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).
  • The technology allows the rapid selection of specific binders (“Phenotype”), physically connected to unique DNA tags (“Genotype”) that work as amplifiable identification barcodes.
  • Philochem has synthesized several DNA-Encoded Chemical Libraries, featuring different designs, that have yielded high affinity and selective binders to a variety of target proteins of pharmaceutical interest.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.